Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with psoriasis: cosentyx® shows promise in chinese study

NCT ID NCT05388916

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx® (secukinumab) for up to 52 weeks. The goal was to see how safe and effective the drug is in real-world settings. Researchers tracked side effects and measured how much the psoriasis improved using a standard skin score.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

42 people

The number who actually took part.

Started

Sep 2022

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chinese pediatric patients aged between 6 to less than 18 years and diagnosed with moderate to severe plaque psoriasis.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients meeting all of the following criteria are eligible for inclusion in this study: * Written assent and informed consent must be obtained as per local regulations prior to any study procedures. * Diagnosed with moderate to severe plaque psoriasis. * Initiating treatment with Cosentyx® or having started Cosentyx® treatment within the last 4 weeks in routine clinical practice, and its prescription is independent of this study. * Aged 6 to less than 18 years at the time they are prescribed Cosentyx®. * Have valid PASI and IGA mod 2011 score at the time they are prescribed Cosentyx®. Exclusion Criteria: Patients meeting any of the following criteria are not eligible for inclusion in this study: * Patients previously treated with other biologics. * Patients participating in other clinical trials or who previously participated in clinical trials within 30 days before Cosentyx® initiation or a period of 5 half-lives of the investigational drug, whichever is longer. * Patients in conditions which in the judgment of the clinical investigator renders the patient unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe chronic plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe chronic plaque psoriasis

Contacts and locations

Locations

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510091, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050000, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450018, China

  • Novartis Investigative Site

    Shenyang, Liaoning, 110004, China

  • Novartis Investigative Site

    Xian, Shanxi, 710004, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310009, China

  • Novartis Investigative Site

    Beijing, 100069, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.